tiprankstipranks
Bolt Biotherapeutics Announces Board Reshuffle and New Appointment
Company Announcements

Bolt Biotherapeutics Announces Board Reshuffle and New Appointment

Pick the best stocks and maximize your portfolio:

Bolt Biotherapeutics (BOLT) just unveiled an update.

Bolt Biotherapeutics, Inc. announced board changes with the resignations of James Healy and Frank D. Lee, effective September 3, 2024; both resignations are amicable without any conflicts. Filling the vacancy, Jakob Dupont, with a robust background in biopharmaceuticals and multiple drug approvals to his credit, joins the board. His term as a Class II member will conclude at the 2026 annual stockholders’ meeting, and he will receive the standard compensation for his role as a non-employee director. Dupont has no undisclosed transactions that could pose conflicts of interest.

Learn more about BOLT stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskBolt Biotherapeutics’ Restructuring Faces Potential Setbacks: A Closer Look
TipRanks Auto-Generated NewsdeskBolt Biotherapeutics Reports Q3 2024 Financial Results
TheFlyBolt Biotherapeutics reports Q3 EPS (40c), consensus (35c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App